Last Updated: 09 Nov 2024
Executive Summary
Utah Medical Products Inc. (UTMD) is a medical device company with a market capitalization of $233.65 million. The company has a strong financial position with an EBITDA of $20.14 million and a profit margin of 34.6%. UTMD's stock price is currently trading at $67.91, which is within its 52-week range of $63.38 to $86.41.
Company Overview
Utah Medical Products Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company's products include surgical instruments, implants, and other medical supplies. UTMD's customers include hospitals, clinics, and other healthcare providers.
Fundamental Analysis
UTMD's financial performance has been strong in recent years. The company's revenue has grown at a CAGR of 5.4% over the past five years. In 2023, UTMD reported revenue of $44.08 million and net income of $14.6 million. The company's gross profit margin is 73.1%, and its operating margin is 37.5%.
UTMD has a strong balance sheet with total assets of $62.2 million and total liabilities of $22.1 million. The company's debt-to-equity ratio is 0.36, which is considered to be a conservative level of leverage.
Technical Analysis
UTMD's stock price has been trading in a range between $63.38 and $86.41 over the past 52 weeks. The stock is currently trading near the middle of this range. The 50-day moving average is $65.98, and the 200-day moving average is $68.60. The relative strength index (RSI) is 52.3, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
UTMD's stock price is likely to continue to trade in a range in the short term. The stock is currently facing resistance at the $70 level, and it is likely to need a catalyst to break out of this range.
Long Term Outlook
UTMD's long-term outlook is positive. The company has a strong financial position and a growing product portfolio. The company is also benefiting from the aging population, which is increasing the demand for medical devices.
Analyst Recommendations
Analysts are generally positive on UTMD's stock. The consensus recommendation is a "buy" with a target price of $75.00.
